Genetic and biological characterization of recombinant HIV type 1 with Env derived from long-term nonprogressor (LTNP) viruses

AIDS Research and Human Retroviruses

Volumn 23, Issue 11, 2007, Pages 1377-1386

  Antoni, Sascha ^a   Walz, Nicole ^a   Landersz, Margot ^a   Humbert, Michael ^a,b   Seidl, Christian ^c   Dittmar, Matthias T ^d   Dietrich, Ursula ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Red Cross Blood Donor Service   (Germany)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; NEF PROTEIN; NEUTRALIZING ANTIBODY; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VPR PROTEIN; HLA B ANTIGEN;

ALLELE; ARTICLE; BASE PAIRING; CONTROLLED STUDY; ENVELOPE GENE; GENE HLA B27; GENE HLA B5701; GENE MUTATION; GENE REPLICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS CHARACTERIZATION; VIRUS GENE; VIRUS LOAD; VIRUS RECOMBINANT; CELL LINE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INNATE IMMUNITY; VIROLOGY; VIRUS REPLICATION;

CELL LINE; GENES, ENV; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HLA-B ANTIGENS; HUMANS; IMMUNITY, NATURAL; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECEPTORS, CCR5; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 38449085741     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0113     Document Type: Article

References (60)

1. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272(5265):1167-1170.
2. Humbert M, Antoni S, Brill B, et al.: Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur J Immunol 2007;37(2):501-515.
3. Saksena NK: Biological and molecular mechanisms in progression and non-progression of HIV disease. AIDS Rev 2001;3(3):133-144.
4. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273(5283):1856-1862.
5. Huang Y, Paxton WA, Wolinsky SM, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2(11):1240-1243.
6. Stewart GJ, Ashton LJ, Biti RA, et al.: Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS 1997;11(15):1833-1838.
7. Yamada T and Iwamoto A: Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol 2000;145(5):1021-1027.
8. Deacon NJ, Tsykin A, Solomon A, et al.: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270(5238):988-991.
9. Kestler HW 3rd, Ringler DJ, Mori K, et al.: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991;65(4):651-662.
10. Lum JJ, Cohen OJ, Nie Z, et al.: Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003;111(10):1547-1554.
11. Mologni D, Citterio P, Menzaghi B, et al.: Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS 2006;20(4):567-574.
12. Migueles SA, Sabbaghian MS, Shupert WL, et al.: HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000;97(6):2709-2714.
13. den Uyl D, van der Horst-Bruinsma IE, and van Agtmael M: Progression of HIV to AIDS: A protective role for HLA-B27? AIDS Rev 2004;6(2):89-96.
14. Paroli M, Propato A, Accapezzato D, Francavilla V, Schiaffella E, and Barnaba V: The immunology of HIV-infected long-term non-progressors - a current view. Immunol Lett 2001;79(1-2):127-129.
15. Carotenuto P, Looij D, Keldermans L, de Wolf F, and Goudsmit J: Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998;12(13):1591-1600.
16. Zhang YJ, Fracasso C, Fiore JR, et al.: Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis 1997;176(5):1180-1187.
17. Pilgrim AK, Pantaleo G, Cohen OJ, et al.: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997;176(4):924-932.
18. Wei X, Decker JM, Liu H, et al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46(6):1896-1905.
19. Derdeyn CA, Decker JM, Sfakianos JN, et al.: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74(18):8358-8367.
20. Bjorndal A, Deng H, Jansson M, et al.: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71(10):7478-7487.
21. Saiki RK, Walsh PS, Levenson CH, and Erlich HA: Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci USA 1989;86(16):6230-6234.
22. Bunce M, O'Neill CM, Barnardo MC, et al.: Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995;46(5):355-367.
23. Pozzi S, Longo A, and Ferrara GB: HLA-B locus sequence-based typing. Tissue Antigens 1999;53(3):275-281.
24. Olerup O and Zetterquist H: HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39(5):225-235.
25. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, and Hahn BH: Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replication-competent and -defective viral genomes. J Virol 1991;65(8):3973-3985.
26. Li Y, Hui H, Burgess CJ, et al.: Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: Evidence for limited defectiveness and complementation. J Virol 1992;66(11):6587-6600.
27. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, and Chen IS: Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987;236(4803):819-822.
28. Cann AJ, Zack JA, Go AS, et al.: Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol 1990;64(10):4735-4742.
29. Collman R, Balliet JW, Gregory SA, et al.: An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 1992;66(12):7517-7521.
30. Dittmar MT, Eichler S, Reinberger S, Henning L, and Krausslich HG: A recombinant virus assay using full-length envelope sequences to detect changes in HIV-1 co-receptor usage. Virus Genes 2001;23(3):281-290.
31. Higgins DG and Sharp PM: Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl Biosci 1989;5(2):151-153.
32. Thompson JD, Higgins DG, and Gibson TJ: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22(22):4673-4680.
33. Zhang M, Gaschen B, Blay W, et al.: Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004;14(12):1229-1246.
34. Kohno T, Mohan S, Goto T, et al.: A new improved method for the concentration of HIV-1 infective particles. J Virol Methods 2002;106(2):167-173.
35. Kimpton J and Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992;66(4):2232-2239.
36. Layne SP, Merges MJ, Dembo M, et al.: Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992;189(2):695-714.
37. Lohrengel S, Hermann F, Hagmann I, et al.: Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 2005;79(16):10237-10246.
38. Leitner T FB, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, and Korber B: HIV Sequence Compendium 2005. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2005. LA-UR 06-0680.
39. Sagar M, Wu X, Lee S, and Overbaugh J: Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006;80(19):9586-9598.
40. Masciotra S, Owen SM, Rudolph D, et al.: Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS 2002;16(14):1887-1898.
41. Wang B, Spira TJ, Owen S, Lal RB, andSaksena NK: HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors. AIDS 2000;14(3):213-223.
42. Shioda T, Oka S, Xin X, et al.: In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: Association of V2 extension with slow disease progression. J Virol 1997;71(7):4871-4881.
43. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66(3):1354-1360.
44. Kiepiela P, Ngumbela K, Thobakgale C, et al.: CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007;13(1):46-53.
45. Rodes B, Toro C, Paxinos E, et al.: Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 2004;18(8):1109-1116.
46. Visco-Comandini U, Yun Z, Paganelli R, et al.: HIV-1 nef mutations and clinical long-term nonprogression. A molecular epidemiology study. J Hum Virol 1998;1(5):320-327.
47. Chui C, Cheung PK, Brumme CJ, et al.: HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2006;22(7):615-618.
48. Troyer RM, Collins KR, Abraha A, et al.: Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005;79(14):9006-9018.
49. Bailey JR, Williams TM, Siliciano RF, and Blankson JN: Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006;203(5):1357-1369.
50. Hutto C, Zhou Y, He J, et al.: Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses. J Virol 1996;70(6):3589-3598.
51. Reimann KA, Parker RA, Seaman MS, et al.: Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol 2005;79(14):8878-8885.
52. Draenert R, Allen TM, Liu Y, et al.: Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med 2006;203(3):529-539.
53. Candotti D, Costagliola D, Joberty C, et al.: Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol 1999;58(3):256-263.
54. Blankson JN, Bailey JR, Thayil S, et al.: Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007;81(5):2508-2518.
55. Blaak H, Brouwer M, Ran LJ, de Wolf F, and Schuitemaker H: In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis 1998;177(3):600-610.
56. Quinones-Mateu ME, Ball SC, Marozsan AJ, et al.: A dual infection/ competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000;74(19):9222-9233.
57. Campbell TB, Schneider K, Wrin T, Petropoulos CJ, and Connick E: Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol 2003;77(22):12105-12112.
58. Alexander L, Weiskopf E, Greenough TC, et al.: Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol 2000;74(9):4361-4376.
59. Blaak H, van der Ende ME, Boers PH, Schuitemaker H, and Osterhaus AD: In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology 2006;353(1):144-154.
60. Marchant D, Neil SJ, and McKnight A: Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol 2006;87(Pt. 2):411-418.